Zenkuda's 6-Month Dosing Claim Is Compelling but Comparator Data Gap Remains the Pivotal Unknown

Zenkuda Achieves Primary Endpoints in Pivotal wAMD Trial

Kodiak Sciences announced that Zenkuda (tarcocimab tedromer) met its primary endpoint in the Phase 3 DAYBREAK study for wet age-related macular degeneration (wAMD), demonstrating meaningful vision gains and rapid, sustained retinal drying. A significant majority (54%) of patients achieved a 6-month dosing interval at year one using strict treat-to-dryness criteria. Zenkuda also showed favorable safety, consistent with aflibercept. Kodiak plans a multi-indication BLA submission for Zenkuda in Q4 2026, based on five positive Phase 3 studies across wAMD, diabetic retinopathy, and retinal vein occlusion.

• Zenkuda demonstrated strong immediacy of clinical effect, matching or exceeding the aflibercept comparator during the loading phase. It achieved robust durability with 54% of wAMD patients maintaining a 6-month (24-week) dosing interval at year one under stringent treat-to-dryness retreatment criteria, positioning it as a potential new standard of care.
• The safety profile of Zenkuda in the DAYBREAK study was favorable and well-tolerated, reporting a 0% intraocular inflammation rate and a 0.5% cataract adverse event rate. These safety findings were consistent with the established safety profile observed with the aflibercept comparator.
• Kodiak Sciences is preparing a multi-indication Biologics License Application (BLA) for Zenkuda, planned for submission in the fourth quarter of 2026. This BLA will be supported by data from five successful Phase 3 studies covering wet AMD, diabetic retinopathy, and retinal vein occlusion, highlighting the drug's broad potential across major retinal vascular diseases.

Zenkuda's DAYBREAK: Efficacy, Safety, and Durability in wAMD

Three recent studies provide clinically relevant data on interventions for neovascular (wet) age-related macular degeneration (nAMD). The TRUCKEE study — a retrospective, multicentric clinical cohort study — evaluated outcomes in 134 eyes of 108 patients switched from brolucizumab to faricimab. After 1 injection of faricimab, a statistically significant reduction in central subfield thickness (CST) was observed (mean −5.25 µm, P = .048), though changes in best-corrected visual acuity (BCVA) and durability were not statistically significant. After 3 injections, numerical improvements were recorded across BCVA (+1.63 letters), CST (−11.28 µm), and retreatment interval (+5.0 days), though none reached statistical significance. The authors noted that the apparent benefit in patients already on maximum VEGF suppression with brolucizumab may suggest the relevance of angiopoietin-2 suppression with faricimab.

A retrospective study evaluating three loading injections of faricimab in 69 treatment-naïve nAMD patients demonstrated significant functional and anatomical improvements. BCVA improved from a mean logarithm of minimal angle of resolution of 0.64 ± 0.41 at baseline to 0.47 ± 0.39 at 3 months (P < 0.001), and central retinal thickness decreased from 424.1 ± 155.5 µm to 266.3 ± 71.7 µm (P < 0.001). Resolution rates for subretinal fluid (SRF), intraretinal fluid (IRF), and serous pigment epithelial detachment were high, with the most pronounced anatomical effects observed in type 2 (88.2%) and type 3 (94.7%) macular neovascularization subtypes.

A 12-month real-world Australian registry study of faricimab in 160 treatment-naïve nAMD eyes reported a mean 4-letter gain in visual acuity (from 61.5 to 65.5 letters), with 48% of eyes attaining a dosing interval of ≥12 weeks by 12 months. Eyes received a mean of 7.2 injections across 7.4 visits, and 71% of lesions became inactive by 12 months, with a mean time to inactivation of 10.3 weeks. Compared with aflibercept 2 mg controls, faricimab demonstrated a significantly higher inactivation rate and a greater proportion of eyes reaching the last injection interval of ≥12 weeks, with the study authors concluding that faricimab had a stronger effect on nAMD lesion activity than aflibercept 2 mg.

Zenkuda's Broad Potential Across Retinal Vascular Diseases

Tarcocimab tedromer (KSI-301) is under clinical investigation across multiple retinal vascular disease indications beyond neovascular age-related macular degeneration. Its antibody-biopolymer conjugate structure is designed to decrease clearance from the eye and extend duration of effect, supporting its evaluation in chronic, VEGF-mediated conditions.

• Diabetic Macular Edema (DME): KSI-301 is being evaluated in Phase 3 trials for DME. Named studies include the DAZZLE, GLEAM, and GLIMMER trials. The knowledge base does not have sufficient information on this aspect.

• Diabetic Retinopathy (DR): KSI-301 is under investigation for diabetic retinopathy more broadly, with clinical trials demonstrating promising data for its management. The knowledge base does not have sufficient information on this aspect.

• Retinal Vein Occlusion (RVO): Phase 3 trials are ongoing for RVO, with the GLOW and BEACON studies named among the relevant investigations. The knowledge base does not have sufficient information on this aspect.

Tabirafusp-ted: A Bispecific Approach Targeting Emerging MoA

Several mechanistic approaches have gained traction in wet AMD beyond conventional VEGF monotherapy. Dual-target inhibition has emerged as a prominent strategy, most notably through simultaneous blockade of VEGF-A and angiopoietin-2 (Ang-2). Faricimab exemplifies this approach: its dual mechanism — involving both VEGF-A and Ang-2 suppression — is proposed to extend therapeutic efficacy beyond what VEGF-A inhibition alone can achieve. Computational modeling has further characterized the molecular basis of these interactions, identifying hydrophobic forces as a central determinant of complex stability across anti-VEGF agents, while noting that faricimab's weaker VEGF-A binding stability may be offset by its dual-target mechanism. The clinical relevance of Ang-2 suppression is further supported by real-world data suggesting that patients already on maximum VEGF suppression with brolucizumab may derive additional benefit upon switching to faricimab, pointing to angiopoietin-2 as a meaningful independent therapeutic axis.

Sustained and long-acting delivery platforms represent a second major mechanistic and technological frontier. EYP-1901, an intravitreal bioerodible insert containing vorolanib — a pan-VEGF receptor inhibitor delivered via Durasert E™ technology — demonstrated a 74% and 71% reduction in anti-VEGF treatment burden at 6 and 12 months respectively following a single administration in the Phase I DAVIO trial, with no dose-limiting toxicity or ocular serious adverse events observed. Complementing this, multifunctional nanotherapeutics such as PLGA@AST/AXI — co-encapsulating astaxanthin and axitinib in an FDA-approved polymer matrix — have demonstrated synergistic antioxidant, anti-inflammatory, and antiangiogenic activity via subconjunctival injection in preclinical models, targeting the reactive oxygen species-rich and inflammatory microenvironment that underlies choroidal neovascularization.

Gene therapy constitutes a third emerging mechanistic paradigm, aiming to provide durable endogenous production of anti-angiogenic proteins following a single administration. AAV-based vectors — including AAV2/8 delivering anti-VEGF single-chain fragment variable (scFv) antibodies — have shown significant therapeutic effect in murine choroidal neovascularization models (p = 0.02 for the scFv format), with the scFv design specifically proposed to mitigate Fc-domain-mediated immune activation in an already-inflamed retinal environment. Active clinical-stage programs include ADVM-022 and RGX-314 for wet AMD, utilizing adeno-associated viral vectors administered via subretinal, intravitreal, or suprachoroidal routes. Broader pipeline strategies also encompass platelet-derived growth factor (PDGF), Tie2, and integrin inhibition, alongside nanocarrier-based delivery and pathways targeting hypoxia and neuroprotection.

Zenkuda's Durability Poised to Reshape Retinal Disease Management

The recent positive Phase 3 DAYBREAK study results for Zenkuda (tarcocimab tedromer) in wet age-related macular degeneration (wAMD) mark a pivotal moment in the ongoing quest for more durable and less burdensome retinal disease therapies. Zenkuda, an anti-VEGF antibody biopolymer conjugate, has shown not only meaningful vision gains and rapid, sustained retinal drying but, critically, enabled a significant majority of patients to achieve a 6-month dosing interval at year one. This extended durability directly addresses the primary challenge with current anti-VEGF treatments: the substantial burden of frequent intravitreal injections that often leads to patient non-adherence and, consequently, suboptimal visual outcomes in the real world.

This development positions Zenkuda as a formidable contender in a crowded therapeutic landscape. Its ability to offer extended dosing could significantly enhance patient quality of life and improve treatment persistence, potentially leading to better long-term visual acuity. The strategic implications are clear:

• Zenkuda's extended durability offers a strong competitive edge against existing anti-VEGF agents and other emerging long-acting therapies, potentially capturing significant market share by reducing the treatment burden.

• Improved patient adherence due to less frequent injections could translate into superior real-world outcomes, a key differentiator in clinical practice.

• The planned multi-indication BLA submission for wAMD, diabetic retinopathy, and retinal vein occlusion solidifies Zenkuda as a cornerstone asset, broadening its market potential and de-risking the company's pipeline.

However, the path forward is not without considerations. The anti-VEGF market is intensely competitive, with a pipeline full of novel mechanisms, sustained-release systems, and gene therapies. While the DAYBREAK results are strong, previous phase 2b/3 studies for KSI-301 in nAMD had 'varied results,' underscoring the need for consistent performance across diverse patient populations. Furthermore, as with any long-acting intravitreal agent, continuous vigilance regarding safety, particularly the potential for intraocular inflammation, remains paramount, given past experiences with other durable therapies. If Zenkuda can maintain its favorable safety profile and demonstrate consistent efficacy across its target indications, it is well-positioned to reshape the standard of care for chronic retinal diseases, offering a much-needed balance of efficacy and reduced treatment burden.